Neutrophil count is associated with myeloid derived suppressor cell level and presents prognostic value for hepatocellular carcinoma patients
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
// Xing Li 1, 2, 3 , Yan-Fang Xing 4 , Ai-Hua Lei 1, 2 , Qiang Xiao 1, 2 , Zhi-Huan Lin 3 , Ying-Fen Hong 3 , Xiang-Yuan Wu 3 , Jie Zhou 1, 2 1 Program in Immunology, Affiliated Guangzhou Women and Children’s Medical Center, Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, China 2 Institute of Human Virology, Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, China 3 Department of Medical Oncology and Guangdong Key Laboratory of Liver Disease, the Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China 4 Department of Nephrology, the Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China Correspondence to: Xiang-Yuan Wu, email: wuxiangy@mail.sysu.edu.cn Jie Zhou, email: zhouj72@mail.sysu.edu.cn Keywords: neutrophil counts, hepatocellular carcinoma, patient selection, prognosis, myeloid derived suppressor cell Received: October 07, 2016 Accepted: February 06, 2017 Published: February 17, 2017 ABSTRACT Myeloid Derived Suppressor Cell (MDSC) has been raised to be a novel target for multiple cancers. However, target agents on MDSC have not display promising efficacy. One of the critical reasons shall be less optimal patient selection. In the present study, we aimed to identify clinical parameters relevant to MDSC level in hepatocellular carcinoma (HCC) patients for future MDSC targeted therapy. In the present study, a series of 55 HCC patients (testing group) and 20 healthy donors were analyzed investigating frequencies of MDSC in peripheral blood mononuclear cells (PBMC). As a result, we found that MDSC level was increased in HCC patients compared to healthy donors (10.33% vs 1.54%, p < 0.0001). The monocytes (r 2 = 0.2875, p < 0.0001), neutrophils (r 2 = 0.3630, p < 0.0001) and platelet counts (r 2 = 0.0828, p = 0.0331) in circulation was positively associated with MDSC level. Then, the prognostic value of the above predictors was determined in a retrospective database of 255 HCC patients (validation group). The baseline characteristics of testing and validation group were similar. Multivariate analysis by Cox regression revealed that neutrophil count was an independent predictor for overall survival (OS) ( p = 0.000, HR 1.065, 95% CI 1.028–1.103), with the rest parameters failed to reach a significant result. In summary, the present study firstly identified blood neutrophil counts was a predictor of MDSC level in PBMC for HCC patients. And, patients with higher neutrophil count level might be the optimal patient subgroup for MDSC targeted therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
Bronte, V., Brandau, S., Chen, S.-H., Colombo, M. P., Frey, A. B., Greten, T. F., Mandruzzato, S., Murray, P. J., Ochoa, A., Ostrand-Rosenberg, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12150 · Cited by 2,751
The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Kumar, V., Patel, S., Tcyganov, E., & Gabrilovich, D. I. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.01.004 · Cited by 2,008
History of myeloid-derived suppressor cells
Talmadge, J. E., & Gabrilovich, D. I. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3581 · Cited by 1,148
Meric-Bernstam, F., Brusco, L., Shaw, K., Horombe, C., Kopetz, S., Davies, M. A., Routbort, M., Piha-Paul, S. A., Janku, F., Ueno, N., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.4165 · Cited by 424 · cited 1×
“In this era of immunotherapy, patient selection for clinical trials on novel targets has become a top issue for presenting efficacy [15, 16].”
BackgroundChiu, D. K., Xu, I. M., Lai, R. K., Tse, A. P., Wei, L. L., Koh, H., Li, L. L., Lee, D., Lo, R. C., Wong, C., et al. (2016) · Hepatology · doi:10.1002/hep.28655 · Cited by 241
Cited by
Myeloid-derived suppressor cells coming of age
Veglia, F., Perego, M., & Gabrilovich, D. (2018) · Nature Immunology · doi:10.1038/s41590-017-0022-x · Cited by 1,767
The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy
Bruni, D., Angell, H. K., & Galon, J. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0285-7 · Cited by 1,586
The immunology of hepatocellular carcinoma
Ringelhan, M., Pfister, D., O’Connor, T., Pikarsky, E., & Heikenwalder, M. (2018) · Nature Immunology · doi:10.1038/s41590-018-0044-z · Cited by 1,076
Neutrophils and PMN-MDSC: Their biological role and interaction with stromal cells
Zhou, J., Nefedova, Y., Lei, A., & Gabrilovich, D. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2017.12.004 · Cited by 339
Self-citationDe Cicco, P., Ercolano, G., & Ianaro, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01680 · Cited by 332
Metadata
- Authors
- Li, X., Xing, Y.-F., Lei, A.-H., Xiao, Q., Lin, Z.-H., Hong, Y.-F., Wu, X.-Y., & Zhou, J.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2017-02-17
- Volume
- 8
- Issue
- 15
- Pages
- 24380-24388
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2590225528
- Cited by
- 56
- References
- 5
- FWCI
- 2.09
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neutrophil count is associated with myeloid derived suppressor cell level and presents prognostic value for hepatocellular carcinoma patients. https://app.cochat.ai/papers/10.18632/oncotarget.15456
- The paper
- Li, X., Xing, Y.-F., Lei, A.-H., Xiao, Q., Lin, Z.-H., Hong, Y.-F., Wu, X.-Y., & Zhou, J. (2017). Neutrophil count is associated with myeloid derived suppressor cell level and presents prognostic value for hepatocellular carcinoma patients. Oncotarget. https://doi.org/10.18632/oncotarget.15456
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.